243 related articles for article (PubMed ID: 35746488)
1. IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China.
Zeng G; Xu L; Feng S; Tang J; Wang X; Li G; Gan Y; Zheng C; Zhao J; Yang Z
Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746488
[TBL] [Abstract][Full Text] [Related]
2. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
[TBL] [Abstract][Full Text] [Related]
3. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
Front Immunol; 2022; 13():967051. PubMed ID: 36159863
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study.
Feng Y; Zhang Y; He Z; Huang H; Tian X; Wang G; Chen D; Ren Y; Jia L; Wang W; Wu J; Shao L; Zhang W; Tang H; Wan Y
EClinicalMedicine; 2022 Jan; 43():101226. PubMed ID: 34901799
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
[TBL] [Abstract][Full Text] [Related]
10. Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
Expert Rev Vaccines; 2022 Dec; 21(12):1873-1881. PubMed ID: 35792752
[TBL] [Abstract][Full Text] [Related]
11. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2.
Badano MN; Sabbione F; Keitelman I; Pereson M; Aloisi N; Colado A; Ramos MV; Ortiz Wilczyñski JM; Pozner RG; Castillo L; Wigdorovitz G; E de Bracco MM; Fink S; Chuit R; Baré P
Mol Immunol; 2022 Mar; 143():94-99. PubMed ID: 35091231
[TBL] [Abstract][Full Text] [Related]
12. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
[TBL] [Abstract][Full Text] [Related]
13. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Eybpoosh S; Biglari A; Sorouri R; Ashrafian F; Sadat Larijani M; Verez-Bencomo V; Toledo-Romani ME; Valenzuela Silva C; Salehi-Vaziri M; Dahmardeh S; Doroud D; Banifazl M; Mostafavi E; Bavand A; Ramezani A
PLoS Pathog; 2023 Nov; 19(11):e1011744. PubMed ID: 37910480
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
17. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
Sedaghat N; Etemadifar M; Lotfi N; Sayahi F; Chitsaz A; Salari M; Ghasemi Movaghar A
Front Immunol; 2023; 14():952911. PubMed ID: 36895555
[TBL] [Abstract][Full Text] [Related]
18. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults.
Wang Q; Ning J; Chen Y; Li B; Shi L; He T; Zhang F; Chen X; Zhai A; Wu C
Front Microbiol; 2022; 13():1008420. PubMed ID: 36406456
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.
Petrović V; Vuković V; Patić A; Marković M; Ristić M
PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321
[TBL] [Abstract][Full Text] [Related]
20. Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
Zeng G; He F; Zhang X; Li G; Wang X; Gan Y; Zheng C; Tang J; Xu L; Zhao J; Feng S; Yang Z
J Med Virol; 2023 May; 95(5):e28797. PubMed ID: 37218584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
